AUTHORS
Jessica Kaplan Altman, MD, Zhuoxin Sun2, Alexander E. Perl, MD3, Li Chen4, John Reagan, MD5, Anita Turk, MD6, Laura C Michaelis, MD7, Steven Gore, MD8, Richard F. Little, MD9, Shahanawaz Jiwani, MBBS, PhD10, Jerald Radich, MD11, Geoffrey L. Uy, MD12, Mark R. Litzow, MD13, Selina Luger, MD, FRCPC14
AFFILIATIONS
1 Nothwestern University, Robert H. Lurie Cancer Center, Chicago, Illinois, United States
2 Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, United States
3 University of Pennsylvania/Abramson Cancer Center, Philadelphia, United States
4 Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, United States
5 Brown University/Rhode Island Hospital, Providence, United States
6 Indiana Univ/Melvin and Bren Simon Cancer Center, Indianapolis, United States
7 Medical College of Wisconsin, Milwaukee, United States
8 National Institutes of Health Clinical Center, Rockville, United States
9 National Cancer Institute, Bethesda, United States
10 National Institutes of Health Clinical Center, Frederick, United States
11 Fred Hutchinson Cancer Center, Seattle, United States
12 Washington University School of Medicine, St. Louis, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 University of Pennsylvania/Abramson Cancer Center, Philadelphia, United States
ABSTRACT
Background and Significance:
Patients (pts) with newly diagnosed (ND) FLT3-ITD AML who achieve remission to venetoclax plus azacitidine (ven/aza) experience high rates of early relapse, relatively short remission duration, and limited survival benefit compared to aza alone. Similar to approaches in intensive chemotherapy (IC), there is interest in adding FLT3 inhibitors to ven/aza for pts with ND AML and FLT3 mutations who are better suited to lower intensity chemotherapy. To date, the merits of this strategy have not been tested in a randomized setting.
Gilteritinib (gilt) is a potent, oral tyrosine kinase inhibitor that is standard therapy for relapsed/refractory AML and a FLT3 mutation. Single institution and multicenter studies of ven, aza, and gilt in ND AML show that a three-drug regimen is associated with high complete remission (CR) rates and MRD negativity within four cycles, but myelosuppression remains a concern. Multi-institutional comparative trials are needed to determine whether FLT3-targeted therapy added to ven/aza improves early endpoints and refine schedules to maximize safety.
Study Design and Methods:
MyeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a National Cancer Institute–led precision medicine platform trial that uses rapid genomic profiling to match patients with ND AML or myelodysplastic syndrome (MDS) to biomarker-driven treatment substudies. Subjects are first enrolled onto the myeloMATCH Master Screening and Reassessment Protocol (NCT05564390) and then assigned to MM1OA-EA02 (NCT06317649) based on the presence of canonical FLT3 mutations.
MM1OA-EA02 is a multisite, pan-NCTN randomized phase 2 trial currently enrolling pts with ND AML, age 60 or older or unfit for intensive therapy with FLT3-ITD or FLT3-TKD (D835/I836) mutation by NGS. Subjects are randomized equally to one of three arms, stratified by age (<70 years vs. older) and FLT3-ITD burden (ITD VAF>33% vs. lower ITD VAF or sole TKD mutation). All study arms contain ven/aza, with two study arms also including gilt in each 28-day cycle. Regimen 1 is ven/aza administered as per VIALE-A study (DiNardo, et al. NEJM 2020). Regimens 2 and 3 are “triplet” regimens and in addition to ven/aza include gilt 80 mg on days 1-28 on regimen 2 similar to published triplet experience or days 8-21 days on regimen 3, similar to FLT3 inhibitor administration with IC. A biopsy is performed between day 14 and 21 of the first cycle of arms 2 and 3 (and per SOC in arm 1) and all treatment is held until count recovery if a morphologic leukemia-free state is achieved. Pts receive up to two induction cycles to achieve remission and then receive ongoing consolidation cycles of therapy. Consolidation in regimens 2 and 3 features shorter ven and aza administration duration to reduce myelosuppression risk.
Response is measured after cycles 2 and 4, including centrally performed MRD by flow cytometry. The primary endpoint is rate of MRD(-) CR (<1 x 10-3) after up to 4 cycles. Key secondary endpoints include safety, response rate, EFS, and OS. The study is powered to detect a 25% absolute improvement in MRD(-) CR rate in either triplet arm from a target accrual of 147 patients.
MM1OA-EA02, currently enrolling in the United States, activated on June 6, 2024 and is anticipated to enroll subjects through November 2028. As of July 1, 2026, 67 pts have been randomized on trial. To date, median age of enrolled patients is 71 years (range 58-86), 41.8% are female, and 77.6% are Caucasian. All treatment-related grades 3-5 non-hematologic AEs and grade 5 hematologic AEs occurring during the first 4 cycles are being evaluated in the first 20 pts enrolled in each triplet arm to ensure safety and tolerability. An interim futility analysis of MRD negative CR rate will be performed when a total of 74 (50% of 147) patients have been randomized and followed for MRD assessment.
DISCLOSURES
Jessica Kaplan Altman, MD: Astellas - Consultancy (Includes expert testimony); Kura Oncology - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); PeerView - Consultancy (Includes expert testimony); Glycomimetrics - Consultancy (Includes expert testimony); Curio - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Dark Blue Therapeutics - Consultancy (Includes expert testimony); Charm Therapeutics - Consultancy (Includes expert testimony); MJH Life Sciences - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); HMP Education - Consultancy (Includes expert testimony); Quetzal - Consultancy (Includes expert testimony); MD Education - Consultancy (Includes expert testimony); Treadwell Therapeutics - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); VJ HemOnc - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Onviv - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Orum - Consultancy (Includes expert testimony); OncLive - Consultancy (Includes expert testimony)